SCHEMBL12437867

SCHEMBL12437867

CN(C)CC(C)(C)CNC(=O)c1ccc(OC2CCN(Cc3ccc4c(c3)c3ccccc3n4C)CC2)c(Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 6/20 0.46
CCR3 P51677 1/20 0.42
POLB P06746 2/20 0.41
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
KDM4E B2RXH2 1/20 0.39
TSHR P16473 1/20 0.39
SLC2A1 P11166 1/20 0.39
RORC P51449 1/20 0.39
HTR1A P08908 1/20 0.38
CYP2D6 P10635 1/20 0.38
DRD2 P14416 1/20 0.38
HTR1D P28221 1/20 0.38
HTR2C P28335 1/20 0.38
HTR1F P30939 1/20 0.38
HTR2B P41595 1/20 0.38
HTR6 P50406 1/20 0.38
CYP3A43 Q9HB55 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12437849 0.93 TP53 (0.45) UTS2RKDM4ETSHRRORC
SCHEMBL12437918 0.87 UTS2R (0.44) UTS2RCCR3POLBMEN1KMT2A
SCHEMBL12437877 0.84 TP53 (0.46) UTS2RKDM4ETSHRRORC
SCHEMBL12437873 0.84 UTS2R (0.47) UTS2RCCR3POLBMEN1KMT2A
SCHEMBL12437855 0.83 TP53 (0.45) UTS2RKDM4ETSHRRORC
SCHEMBL12437923 0.82 TP53 (0.44) UTS2RKDM4ETSHRRORC
SCHEMBL12437888 0.82 TP53 (0.47) KDM4ETSHRRORC
SCHEMBL12437774 0.81 UTS2R (0.49) UTS2RCCR3POLBMEN1KMT2A
SCHEMBL12437857 0.80 TP53 (0.45) UTS2RKDM4ERORC
SCHEMBL12437755 0.80 UTS2R (0.47) UTS2RCCR3POLBSLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178066-A1 Hydroxypiperidine derivatives and uses thereof AVALON PHARMACEUTICALS 2011-07-21 US disclosed
US-20110178066-A1 Hydroxypiperidine derivatives and uses thereof AVALON PHARMACEUTICALS 2011-07-21 US disclosed
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof AVALON PHARMACEUTICALS 2009-02-05 US disclosed
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof AVALON PHARMACEUTICALS 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178066-A1 Hydroxypiperidine derivatives and uses thereof HPGDS, HPGD, DPYD UTS2R 854/4885CCR3 2505/4885POLB 675/4885
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof HPGDS, HPGD, DPYD UTS2R 854/4885CCR3 2505/4885POLB 675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.